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OBJECTIVES We sought to compare contrast-enhanced magnetic resonance imaging (ceMRI) with nuclear
metabolic imaging for the assessment of myocardial viability in patients with chronic ischemic
heart disease and left ventricular (LV) dysfunction.
BACKGROUND Contrast-enhanced MRI has been shown to identify scar tissue in ischemically damaged
myocardium.
METHODS Twenty-six patients with chronic coronary artery disease and LV dysfunction (mean ejection
fraction 31 11%) underwent 18F-fluorodeoxyglucose (FDG) positron emission tomography
(PET), technetium-99m tetrofosmin single-photon emission computed tomography
(SPECT), and ceMRI. In a 17-segment model, the segmental extent of hyperenhancement
(SEH) by ceMRI, defined as the relative amount of contrast-enhanced tissue per myocardial
segment, was compared with segmental FDG and tetrofosmin uptake by PET and SPECT.
RESULTS In severely dysfunctional segments (n  165), SEH was 9  14%, 33  25% (p  0.05), and
80  23% (p  0.05) in segments with normal metabolism/perfusion, metabolism/perfusion
mismatch, and matched defects, respectively. Segmental glucose uptake by PET was inversely
correlated to SEH (r  0.86, p  0.001). By receiver operator characteristic curve analysis,
the area under the curve was 0.95 for the differentiation between viable and non-viable
segments. At a cutoff value of 37%, SEH optimally differentiated viable from non-viable
segments defined by PET. Using this threshold, the sensitivity and specificity of ceMRI to
detect non-viable myocardium as defined by PET were 96% and 84%, respectively.
CONCLUSIONS Contrast-enhanced MRI allows assessment of myocardial viability with a high accuracy,
compared with FDG-PET, in patients with chronic ischemic heart disease and LV
dysfunction. (J Am Coll Cardiol 2003;41:1341–8) © 2003 by the American College of
Cardiology Foundation
Assessment of residual myocardial viability in patients with
chronic coronary artery disease and left ventricular (LV)
dysfunction is of great clinical importance (1–4). Several
techniques analyzing the morphologic (5), functional (6),
cellular (7), or metabolic (8) integrity of the myocardium
have been introduced into clinical medicine. Each of these
methods has specific advantages for the diagnosis of myo-
cardial viability, but none allows direct visualization of the
transmural extent of viable and non-viable tissue. Recently,
contrast-enhanced magnetic resonance imaging (ceMRI)
has been proposed as an alternative imaging modality for the
assessment of myocardial viability. In several experimental
studies, the relationship between hyperenhanced myocar-
dium at ceMRI and myocardial necrosis determined by
histology has been investigated (9–14). Using high spatial
resolution techniques, the size and shape of hyperenhanced
areas at ceMRI were identical to areas of irreversible injury
defined by tetrazolium staining (15). Moreover, ceMRI
allows one to distinguish between regions with reversible
and irreversible myocardial injury, depending on the trans-
mural extent of hyperenhancement (14,15). Furthermore,
the transmural extent of hyperenhancement has been shown
to be predictive of recovery of segmental contractile function
after myocardial revascularization in experimental studies
(16) and in patients with acute myocardial infarctions and
chronic ischemic heart disease (17,18).
The aim of this study was to compare ceMRI with
nuclear metabolic imaging using 18F-fluorodeoxyglucose
(FDG) positron emission tomography (PET) for the detec-
tion of myocardial viability in patients with chronic ischemic
heart disease and LV dysfunction.
METHODS
Patient population. Twenty-six consecutive patients with
LV dysfunction scheduled for myocardial viability assess-
ment were scanned with both PET and ceMRI within three
weeks of each other. All patients were in a stable clinical
condition, and there were no ischemic events or mechanical
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interventions in the period between the different examina-
tions. Three patients were scanned within two weeks after
an acute myocardial infarction and were excluded from the
final analysis. The baseline characteristics of the patient
population are given in Table 1. The Committee on
Research Involving Human Subjects of the Vrije Univer-
siteit Medical Center, Amsterdam, approved the study
protocol, and all subjects gave written, informed consent.
Imaging protocols. MAGNETIC RESONANCE IMAGING. Im-
ages were acquired on a 1.5-tesla whole-body scanner
(Magnetom Sonata by Siemens, Erlangen, Germany) with
the patient in a supine position using a four-element,
phased-array cardiac coil. Scout images were acquired in
long-axis and short-axis orientations for planning of the
final double-oblique long-axis and short-axis views. Elec-
trocardiographically gated cine images were acquired using a
segmented steady-state free precession sequence (true FISP;
echo time/repetition time [TE/TR] of 1.2/3.2 ms; resolu-
tion of 1.3 1.8 5 mm). Three long-axis views and seven
to 11 short-axis views 1 cm apart, covering the whole LV,
were obtained during repeated breath-holds. A gadolinium-
based contrast agent (Magnevist 0.2 mmol/kg; Schering
AG, Berlin, Germany) was then administered intravenously
using an automated injection at a rate of 3 ml/s. After 15 to
20 min, contrast-enhanced images were acquired in the
same orientation as the cine images, using a segmented
inversion-recovery, gradient-echo pulse sequence triggered
to end diastole (19). The inversion time was set to null the
signal of normal myocardium after contrast administration
(typically 250 to 300 ms) and was adjusted in the course of
the investigation if necessary. Other parameters of the
sequence were TR/TE of 9.6/4.4 ms, flip angle 25°, matrix
208  256, and a typical voxel size of 1.6  1.3  5.0 mm.
FDG-PET IMAGING. All patients underwent hyper-
insulinemic-euglycemic clamping (20). Scans were per-
formed in a two-dimensional mode, using an ECAT
EXACT HR (Siemens/CTI, Knoxville, Tennessee), after
an intravenous injection of 370 MBq of FDG. The dynamic
scan consisted of 39 frames with variable frame lengths for
a total time of 60 min. All dynamic scan data were corrected
for physical decay of 18F and for dead time, scatter, and
random and measured photon attenuation. The images were
reconstructed using filtered backprojection with a Hanning
filter at the Nyquist frequency. This resulted in a transaxial
spatial resolution of 7 mm full width at half maximum.
Additionally, each patient underwent technetium-99m-
tetrofosmin single-photon emission computed tomography
(SPECT) for assessment of rest blood flow.
Data analysis. SEGMENTAL MODEL. For each imaging
modality, an identical 17-segment model was used dividing
the LV into six basal, six midventricular, and four distal
segments, and the apex (21). The basal, midventricular, and
distal segments were evaluated in short-axis images, whereas
the apical cap was evaluated in the two-chamber long-axis
view with ceMRI and in the vertical long-axis view with
PET and SPECT. By convention, the most basal short-axis
slice used for analysis was located just below and exclusive of
the LV outflow tract.
MAGNETIC RESONANCE IMAGING. All MRI images were
first previewed on a personal computer work station, using
commercial software (Radworks version 5.0, Applicare
Medical Imaging, Zeist, The Netherlands). To compose the
basal, midventricular, and distal segments, MRI data of a
maximum of three short-axis slices were averaged. All
short-axis slices were projected on the two-chamber long-
axis view and were allocated to the different positions
according to their relationship to the papillary muscles: the
midventricular slices at the level of the papillary muscles and
the basal and distal slices above or below the papillary
muscles. Each basal and midventricular slice was divided
into six equidistant sectors angulated 60° apart starting from
the posterior insertion of the right ventricular free wall into
the LV myocardium. The distal slices were segmented into
four equidistant sectors angulated at 90°.
EVALUATION OF CONTRAST-ENHANCED IMAGES. The
MASS software (Medis, Leiden, The Netherlands) was
used for quantitative analysis. Each myocardial sector was
evaluated for the presence of hyperenhancement, defined as
an area of signal enhancement 3 SD of the signal of
Abbreviations and Acronyms
AUC  area under the curve
ceMRI  contrast-enhanced magnetic resonance
imaging
EDWT  end-diastolic wall thickness
FDG  18F-fluorodeoxyglucose
LV  left ventricle or ventricular
PET  positron emission tomography
ROC  receiver operator characteristic
ROI  region of interest
SHE  segmental extent of hyperenhancement
SPECT  single-photon emission computed tomography
Table 1. Baseline Characteristics of the Patient Population
Mean age in yrs (range) 65 (41–81)
Males/females 18/5
History of myocardial infarction 18 (78%)
Time interval betwen infarction
and viability studies (months)
150  83
Q waves on ECG 15 (65%)
Coronary angiography 21 (91%)
Single-vessel disease 4
Two-vessel disease 5
Three-vessel disease 12
Previous revascularization 14 (61%)
CABG 2
PTCA 7
CABG and PTCA 5
Mean ejection fraction by MRI (%) 31  11
Data are presented as the mean value  SD or number (%) of subjects.
CABG  coronary artery bypass graft surgery; ECG  electrocardiogram; MRI
 magnetic resonance imaging; PTCA  percutaneous transluminal coronary
angioplasty.
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non-enhanced myocardium. The total myocardial area and
contrast-enhanced area per sector were traced manually.
The extent of contrast enhancement was expressed as a
percentage of the total myocardial area (Ahyperenhanced/
Amyocardium  100, where A denotes area) (Fig. 1). The
MRI data of corresponding sectors on different short-axis
slices used to compose one myocardial segment were aver-
aged to give one final value for the segmental extent of
hyperenhancement (SEH).
ASSESSMENT OF SEGMENTAL FUNCTION. Wall motion was
assessed by visual interpretation for each myocardial sector
on each cross section using a five-point scale: 1  normal
contractility; 2  mild to moderate hypokinesia; 3  severe
hypokinesia; 4  akinesia; and 5  dyskinesia. The results
of different sectors composing the different myocardial
segments were averaged. Additionally, segmental end-
diastolic wall thickness (EDWT) and wall thickening were
determined by manual tracing of endocardial and epicardial
borders in end-diastolic and end-systolic stop-frame images,
excluding trabeculations and papillary muscles.
FDG-PET. Data were analyzed blinded to the MRI results
and patient data, using a SUN work station (SUN Micro-
system, Inc.) with Siemens/CTI software. Transaxial im-
ages were reoriented according to the anatomic axis of the
heart. Reconstructed slices were displayed as short-axis
slices and horizontal as well as vertical long-axis slices.
Short-axis slices were oriented in the same way as described
for ceMRI, using the posterior insertion of the right
ventricular wall with the LV as a landmark. Regions of
interest (ROIs) were defined manually on each of the
short-axis slices using the same segmentation model as for
ceMRI. Corresponding ROIs from a variable number of
slices were grouped in each patient to compose the 17
segments. For each segment, mean tracer uptake was
calculated. Uptake of FDG in each segment was normalized
to the myocardial segment with maximal tetrofosmin up-
take.
DEFINITION OF VIABILITY BY PET. Segments with normal
perfusion (tetrofosmin uptake 50%) and metabolism
(FDG uptake 50%) and segments with reduced perfusion
(tetrofosmin uptake 50%) and normal or increased me-
tabolism (mismatch) were considered viable. Segments with
reduced perfusion and reduced metabolism (matched de-
fect) were considered non-viable (22–25). In two patients
with a left bundle branch block, dysfunctional segments in
the septum demonstrating FDG uptake 50% were con-
sidered viable if tetrofosmin uptake exceeded 50%, as
FDG-PET may underestimate viability in the septal region
in the presence of left bundle branch block (26).
Statistics. Data are expressed as the mean value  SD. To
compare the segmental results for EDWT, wall thickening,
SEH, and FDG uptake by PET, depending on cardiac
function, and to compare the segmental results for EDWT,
wall thickening, and SEH, depending on the viability status
as defined by PET, the unpaired Student t test at the
Bonferroni-adjusted individual significance level (0.05/24;
number of comparisons  24) was performed. Recently
described non-parametric analysis of overall sensitivities and
specificities, as well as areas under the receiver operator
characteristic (ROC) curves, were applied (27,28). The area
under the ROC curve (AUC) was considered as a measure
of accuracy of ceMRI to discriminate between viable and
non-viable myocardium, as defined by PET. The ROC
curve analysis was also used to assess the optimal cutoff
point of the increase of SEH, as determined by ceMRI for
the detection of segments with myocardial non-viability.
Sensitivity and specificity were determined for viability or
non-viability, as defined by PET. Computations were per-
formed using SAS version 8.02 for Windows.
RESULTS
A total of 391 segments in 23 patients were analyzed. Table
2 summarizes the results for EDWT, wall thickening, SEH,
and FDG uptake by PET, depending on segmental cardiac
function. Segments with normal wall motion or mild to
moderate dysfunction showed normal metabolism and per-
fusion in 225 (99%) of 226 segments; of these, 169 segments
demonstrated no hyperenhancement and 57 segments re-
vealed subendocardial enhancement only (mean SEH 15 
11%). Segments with severe dysfunction (n  165) showed
normal metabolism/perfusion in 78 segments, a metabo-
lism/perfusion mismatch in 38 segments, and a matched
defect in 49 segments. Table 3 summarizes the results for
SEH, EDWT, and wall thickening, depending on the
viability status defined by nuclear imaging. Of 78 dysfunc-
tional segments with normal perfusion and metabolism, 50
segments (64%) showed no hyperenhancement and 28
segments (36%) demonstrated subendocardial hyperen-
hancement (25  13% SEH). In 38 mismatched segments,
there were six segments (16%) without hyperenhancement
Figure 1. Analysis of contrast-enhanced images. (Large panel) The
posterior insertion of the right ventricular wall into the left ventricle served
as a landmark for the definition of sectors in the short-axis slices. (Small
panel) Total myocardial area per sector (outer white line, arrows) and
contrast-enhanced area per sector (inner white line, arrowheads) were
traced manually, and the amount of hyperenhancement was expressed as
the percentage relative to total myocardial area.
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and 32 segments with hyperenhancement (40 23% SEH).
In 49 segments with a matched defect, only one segment
(2%) demonstrated no hyperenhancement, whereas 48 seg-
ments showed a large extent of hyperenhancement (82 
20% SEH). A strong inverse correlation was found between
FDG uptake by PET and SEH by ceMRI (r  0.86, p 
0.001). The correlation between FDG uptake and EDWT
(r  0.51, p  0.001) or wall thickening (r  0.41, p 
0.001) was lower than that with ceMRI. Figure 2 shows
mean SEH by ceMRI categorized according to FDG
uptake by PET.
Accuracy of ceMRI to predict viability by FDG-PET.
To assess the ability of ceMRI to discriminate between
viable and non-viable segments, as defined by FDG-PET,
ROC analysis was performed on all segments with severe
dysfunction. The AUC of ceMRI to predict myocardial
viability defined by FDG-PET was 0.95 (95% confidence
interval 0.93 to 0.97) (Fig. 3). A threshold of 37% SEH
was identified to yield optimal sensitivity and specificity for
the differentiation of viable and non-viable segments de-
fined by FDG-PET. Using this cutoff value, 100 segments
were assessed as viable and 65 segments as non-viable by
ceMRI. Compared with FDG-PET, the sensitivity and
specificity of ceMRI for the identification of non-viable
myocardium were 96% and 84%, respectively. Table 4
displays different sensitivity and specificity levels derived
from the ROC curve for the detection of non-viable
myocardium, as defined by PET, according to different
thresholds of SEH, as assessed by ceMRI.
Relationship of viability status by ceMRI and FDG-PET.
Table 5 relates the viability by ceMRI to the viability status
by FDG-PET. Concordance between the techniques was
high for segments with normal metabolism/perfusion (95%)
or a matched defect (96%). Mismatched segments demon-
strated SEH 37% in 24 segments (63%). Uptake of FDG
was lower in the mismatched segments with SEH 37%
compared with the mismatched segments with SEH 37%
(54  3% vs. 71  9%; p  0.001). Figure 4 shows
representative images of a patient with akinesia of the
inferior wall, subendocardial hyperenhancement on ceMRI,
and a metabolism/perfusion mismatch by PET and
SPECT.
Complete agreement between PET and ceMRI was
present in 11 patients. Figure 5 shows an example of a
patient with a match between ceMRI and PET. In the
remaining 12 patients, the methods differed by one segment
in four patients, two segments in five patients, and three
segments in three patients.
DISCUSSION
Previous studies have suggested that myocardial hyperen-
hancement by ceMRI represents irreversible myocardial
injury, thus allowing determination of myocardial viability.
The aim of this study was to compare assessment of
myocardial viability by ceMRI with metabolic imaging
using FDG-PET, which is considered the in vivo reference
standard for viability determination. For this purpose, we
quantitatively analyzed the segmental extent of scar tissue
Table 3. Magnetic Resonance Imaging Parameters in Severely
Dysfunctional Segments (n  165) According to the Viability
Status by Positron Emission Tomography
Viability Status by PET
MRI Parameters
SEH (%)
EDWT
(mm)
Wall
Thickening
(mm)
Normal (n  78) 9  14 7  2 1  0.7
Mismatch (n  38) 33  25* 6  2 0.6  0.6
Non-viable (n  49) 80  23*† 4  1*† 0.1  0.4*†
*p  0.05 vs. viable segments. †p  0.05 vs. mismatched segments. Data are
presented as the mean value  SD.
MRI  magnetic resonance imaging; PET  positron emission tomography;
other abbreviations as in Table 2.
Figure 2. Bar graph showing mean segmental extent of hyperenhancement
by contrast-enhanced magnetic resonance imaging categorized according
to 18F-fluorodeoxyglucose (FDG) uptake by positron emission tomography
(PET).
Table 2. Results of Magnetic Resonance Imaging Parameters and uptake by Positron Emission
Tomography, According to Wall Motion
Wall Motion
No. of
Segments
EDWT
(mm)
Wall Thickening
(mm)
SEH
(%)
FDG Uptake
(%)
Normal 156 7.8  1.7 4  1 2  8 86  12
Mild to moderate hypokinesia 70 7.1  1.6 2  1* 9  13* 82  15
Severe hypokinesia 65 6.7  2.0* 1  0.7* 14  20* 75  17*
Akinesia/dyskinesia 100 5.5  1.6* 0.2  0.3* 50  38* 54  22*
*p  0.05 vs. normal. Data are presented as the mean value  SD.
EDWT  end-diastolic wall thickness; FDG 18F-fluorodeoxyglucose; SEH  segmental extent of hyperenhancment.
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by ceMRI and compared it with segmental FDG uptake by
PET. The results demonstrate that non-viable segments by
FDG-PET demonstrate a significantly larger extent of
hyperenhancement compared with segments identified as
viable by FDG-PET. Moreover, we found a progressive
increase of scar among segments with normal perfusion/
metabolism, reduced perfusion but preserved metabolism
representing hibernating myocardium, and a matched per-
fusion/metabolism defect (Table 3). Using ROC analysis,
the AUC was 0.95 for the discrimination of viable myocar-
dium from scar, as defined by FDG-PET, reflecting high
diagnostic accuracy. A cutoff value of 37% SEH was
identified from the ROC curve to differentiate non-viable
from viable myocardium with optimal sensitivity and spec-
ificity. Thus, ceMRI allows accurate assessment of myocar-
dial viability in patients with ischemic heart disease and
severely reduced LV function.
Comparison with previous studies. The results of the
present study compare favorably with previous reports
relating the extent of fibrosis to FDG-PET findings. Maes
et al. (29) observed a similar extent of percentage volume
fibrosis assessed on the basis of myocardial biopsy data
(35  25%) in segments showing non-viability by PET.
Dakik et al. (30) demonstrated that 30% of transmural
scarring correlated with a lack of improvement in function
after revascularization. In a recent animal experiment study-
ing the relationship between ceMRI and regional inotropic
response, Gerber et al. (31) demonstrated that only seg-
ments with 33% transmural extent of CE had inotropic
reserve during dobutamine infusion, whereas segments with
a higher (33%) transmural extent of CE did not. The
results of the present study are also in close agreement with
a recent report by Klein et al. (32), who evaluated ceMRI
and FDG-PET for viability assessment in a similar patient
population. In their study, the AUC was 0.93, with a
sensitivity of 86% and a specificity of 94% for the detection
of non-viability by FDG-PET. Additionally, a high corre-
lation was reported between semiquantitative estimates of
scar severity by ceMRI and PET (r  0.91). Similarly, we
observed a strong correlation between the segmental extent
of scar by ceMRI and FDG uptake by PET (r  0.86).
This finding closely agrees with the results of a previous
study relating the amount of fibrosis at histologic examina-
tion with regional thallium-201 activity (r  0.85) in
patients with chronic ischemic heart disease (33). Other
functional parameters that have been useful for the charac-
terization of myocardial viability, such as regional wall
thickness and wall thickening (5), correlated less well with
FDG-PET, which is in line with the results reported by
Klein et al. (32).
A high concordance was found between ceMRI and PET
for assessment of the viability status of dysfunctional seg-
ments with normal perfusion/metabolism or a matched
defect (Table 3). In segments with preserved metabolism
but reduced perfusion (mismatch), reflecting hibernating
myocardium, the results were less explicit. Sixty-three per-
cent of segments scored viable and 37% of segments scored
non-viable by ceMRI, using the threshold value of 37%
SEH. The amount of enhancement averaged 33  25% in
this group of segments (Table 3). A similar extent of volume
fibrosis at histologic examination in segments with hiber-
nating myocardium of 6 months duration (41.9  22.1%)
has been reported in a previous study (34). It should be
Table 5. Viability by Contrast-Enhanced Magnetic Resonance
Imaging According to Viability Status by Positron
Emission Tomography
Viability Status by
PET
Viability by ceMRI
SEH <37% SEH >37%
Normal (n  78) 74 4
Mismatch (n  38) 24 14
Non-viable (n  49) 2 47
ceMRI  contrast-enhanced magnetic resonance imaging; PET  positron emission
tomography; SEH  segmental extent of hypersensitivity.
Figure 3. The receiver operator characteristic analysis of the differentiation
between viable and non-viable segments by contrast-enhanced magnetic
resonance imaging using 18F-fluorodeoxyglucose-positron emission to-
mography as a reference standard.
Table 4. Sensitivity and Specificity of Different Thresholds of
Segmental Extent of Hyperenhancement for the Detection of
Non-Viable Myocardium by 18F-Fluorodeoxyglucose–Positron
Emission Tomography
SEH Threshold (%) Sensitivity (%) Specificity (%)
30 96 76
35 96 80
40 94 85
45 92 88
50 90 89
55 84 91
60 84 93
65 80 95
70 76 96
SEH  segmental extent of hyperenhancement.
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considered that myocardial viability is a gradual phenome-
non and that the dichotomous definition of viability used in
the present study for ceMRI is related to the dichotomous
definition of viability for FDG-PET. Thus, a segment
with 50% SEH, although scored non-viable by ceMRI in
the present study, demonstrates a large rim of viable
myocardium. Even if recovery of function after revascular-
ization is unlikely, restoration of blood flow may contribute
to prevent further ischemic injury and improve the clinical
status and prognosis of the patient (34,35). Moreover, while
the cutoff value of 37% SEH is mathematically the best
threshold, one might wish to choose a different cutoff value
to minimize the chances of missing viable myocardium.
Thus, as demonstrated in Table 4, a threshold of 50% would
increase the specificity of detecting non-viable myocardium,
thereby increasing the amount of segments scored viable by
ceMRI.
Study limitations. As in all studies comparing different
imaging modalities, there is the possibility of image mis-
alignment, which may account for some of the discrep-
ancies between the FDG-PET and ceMRI results. More-
over, variability may be associated with averaging of
MRI as well as PET and SPECT data, which was per-
formed in order to compose the 17 myocardial segments.
The MRI sequence used is susceptible to artifacts asso-
ciated with patient movement or imperfect breath-holding,
which can be erroneously interpreted as areas of hyper-
enhancement. Recovery of myocardial function after revas-
cularization was not assessed in the present study. Thus,
conclusions on the functional recovery of dysfunctional
segments deemed viable by ceMRI cannot be drawn from
the present study. Others have shown that recovery of
function after revascularization is related to the transmural
extent of hyperenhancement in patients with ischemic
cardiomyopathy (17), with a gradual decrease in functional
recovery paralleled by an increasing transmurality of hyper-
enhancement. In the study of Kim et al. (17), 73% (44/60)
of segments with no hyperenhancement or with 50%
transmural hyperenhancement improved function after re-
vascularization. Based on these results, one might speculate
that most of the dysfunctional segments assessed as viable
by ceMRI in our study might have recovered function after
restoration of adequate blood flow. Nevertheless, deter-
mination of contractile function after revascularization
would be helpful to establish the relative importance of
ceMRI and FDG-PET to predict functional recovery,
which is considered an important outcome variable. An-
other limitation is that although the prognostic relevance of
FDG-PET to predict morbidity and mortality is well
established (2,36), data on ceMRI are scarce (37). Thus, the
prognostic relevance of ceMRI needs to be established in
future studies.
Conclusions. In patients with chronic ischemic heart dis-
ease and LV dysfunction, ceMRI allows detection of myo-
cardial viability with a high accuracy, as compared with
FDG-PET. Therefore, ceMRI should be considered as an
alternative technique for assessment of myocardial viability
in patients with chronic coronary artery disease and may be
an alternative imaging modality in centers where FDG-
PET is unavailable or less economical. Future studies should
be directed at assessing the prognostic value of ceMRI to
predict morbidity and mortality in patients with chronic
ischemic heart disease and LV dysfunction.
Figure 4. (Top row) Representative tetrofosmin SPECT (left panel), FDG-PET (middle panel), and contrast-enhanced magnetic resonance imaging
(ceMRI) (right panel) images of the basal myocardial segments of the same patient. The SPECT image shows a perfusion defect extending from the septum
to the inferior wall (white arrowheads). FDG-PET demonstrates preserved glucose metabolism in the same region (white arrowheads). On the ceMRI
image, a subtle subendocardial area of hyperenhancement is seen extending from the inferoseptal to posterolateral myocardium (black arrowheads).
(Bottom row) End-diastolic (left panel) and end-systolic (right panel) frames of the corresponding cine images. An area of akinesia extends along the same
region as the hyperenhancement area. This area corresponds to non-contracting but viable myocardium. SPECT  single photon emission computed
tomography. Other definitions are defined in Figure 2.
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